Trung Huynh
Stock Analyst at UBS
(4.12)
# 407
Out of 4,829 analysts
43
Total ratings
53.33%
Success rate
14.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trung Huynh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLDX Celldex Therapeutics | Maintains: Buy | $44 → $38 | $18.33 | +107.31% | 2 | May 9, 2025 | |
| INSM Insmed | Maintains: Buy | $110 → $109 | $65.08 | +67.49% | 5 | May 9, 2025 | |
| AMGN Amgen | Maintains: Neutral | $319 → $315 | $265.86 | +18.48% | 4 | May 2, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,100 → $1,050 | $734.57 | +42.94% | 8 | May 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $768 → $633 | $527.78 | +19.94% | 2 | Apr 30, 2025 | |
| PFE Pfizer | Maintains: Neutral | $24 → $25 | $22.28 | +12.21% | 6 | Apr 30, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $60 → $54 | $46.45 | +16.25% | 5 | Apr 11, 2025 | |
| CABA Cabaletta Bio | Maintains: Buy | $10 → $7 | $1.19 | +488.24% | 2 | Apr 1, 2025 | |
| JSPR Jasper Therapeutics | Initiates: Buy | $38 | $4.52 | +740.71% | 1 | Feb 13, 2025 | |
| KYTX Kyverna Therapeutics | Initiates: Buy | $13 | $2.11 | +516.11% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $170 → $175 | $154.22 | +13.47% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $126 | $75.97 | +65.85% | 3 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $170 | $184.60 | -7.91% | 1 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $7.10 | - | 1 | Mar 23, 2021 |
Celldex Therapeutics
May 9, 2025
Maintains: Buy
Price Target: $44 → $38
Current: $18.33
Upside: +107.31%
Insmed
May 9, 2025
Maintains: Buy
Price Target: $110 → $109
Current: $65.08
Upside: +67.49%
Amgen
May 2, 2025
Maintains: Neutral
Price Target: $319 → $315
Current: $265.86
Upside: +18.48%
Eli Lilly and Company
May 2, 2025
Maintains: Buy
Price Target: $1,100 → $1,050
Current: $734.57
Upside: +42.94%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Neutral
Price Target: $768 → $633
Current: $527.78
Upside: +19.94%
Pfizer
Apr 30, 2025
Maintains: Neutral
Price Target: $24 → $25
Current: $22.28
Upside: +12.21%
Bristol-Myers Squibb Company
Apr 11, 2025
Maintains: Neutral
Price Target: $60 → $54
Current: $46.45
Upside: +16.25%
Cabaletta Bio
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $1.19
Upside: +488.24%
Jasper Therapeutics
Feb 13, 2025
Initiates: Buy
Price Target: $38
Current: $4.52
Upside: +740.71%
Kyverna Therapeutics
Oct 10, 2024
Initiates: Buy
Price Target: $13
Current: $2.11
Upside: +516.11%
Jul 21, 2023
Maintains: Neutral
Price Target: $170 → $175
Current: $154.22
Upside: +13.47%
Mar 7, 2023
Maintains: Outperform
Price Target: $125 → $126
Current: $75.97
Upside: +65.85%
Nov 18, 2022
Initiates: Outperform
Price Target: $170
Current: $184.60
Upside: -7.91%
Mar 23, 2021
Upgrades: Outperform
Price Target: n/a
Current: $7.10
Upside: -